Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus PERIACTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus PERIACTIN.
DRIXORAL vs PERIACTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Category C
Category C
Antihistamine/Decongestant
Antihistamine